BANJA LUKA (Bosnia and Herzegovina), January 21 (SeeNews) – Serbian drug maker Hemofarm, a unit of Germany's Stada, plans to invest 22 million euro ($25.5 million) in its production plants in Serbia, Bosnia and Montenegro this year, Belgrade-based media reported on Wednesday.
At least 12 million euro will be invested in the modernization of production operations, news agency Tanjug reported, quoting Hemofarm director Ronald Seelinger.
New investments are planned to increase capacity for the production of ampoules at Hemofarm’s plant in Serbia's Vrsac as well as for the nasal spray production in Podgorica.
Seelinger said Hemofarm produced a record 200 million packs and 4 billion tablets in 2014.
($=0.8656 euro)